Correlations Between Early MRI Parameters and Long-Term Clinical Outcomes in Phase 3 and Open-Label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study

被引：0
|
作者：
Arnold, Douglas [1 ,2 ]
Freeman, Leorah [3 ]
Hartung, Hans-Peter [4 ,5 ,6 ,7 ]
Montalban, Xavier [8 ]
Cohen, Jeffrey [9 ]
Bar-Or, Amit [10 ,11 ]
Steinman, Lawrence [12 ]
DeLuca, John [13 ,14 ]
Sheffield, James [15 ]
Cheng, Chun-Yen [15 ]
Riolo, Jon [15 ]
Pachai, Chahin [15 ]
Cree, Bruce A. C. [16 ]
机构：
[1] NeuroRx Res, Montreal, PQ, Canada
[2] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada
[3] Univ Texas Austin, Dell Med Sch, Austin, TX USA
[4] Heinrich Heine Univ, Med Fac, Dusseldorf, Germany
[5] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia
[6] Med Univ Vienna, Dept Neurol, Vienna, Austria
[7] Palacky Univ Olomouc, Dept Neurol, Olomouc, Czech Republic
[8] Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain
[9] Cleveland Clin, Mellen Ctr MS Treatment & Res, Cleveland, OH USA
[10] Univ Penn, Ctr Neuroinflammat & Expt Therapeut, Philadelphia, PA USA
[11] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA USA
[12] Stanford Univ, Dept Neurol & Neurol Sci, Beckman Ctr Mol Med, Med Ctr, Stanford, CA USA
[13] Kessler Fdn, West Orange, NJ USA
[14] Rutgers New Jersey Med Sch, Dept Phys Med Rehabil & Neurol Neurosci, Newark, NJ USA
[15] Bristol Myers Squibb, Princeton, NJ USA
[16] Univ Calif San Francisco, Weill Inst Neurosci, Dept Neurol, San Francisco, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1661/518
引用
收藏
页码：1050 / 1051
页数：2
相关论文
共 50 条
  • [21] Safety patterns with ozanimod during phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
    Selmaj, K. W.
    Ziemssen, T.
    Comi, G.
    Hartung, H. -P.
    Singal, M.
    Riolo, J. V.
    Cheng, C. -Y.
    Sheffield, J. K.
    Minton, N.
    Vermersch, P.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 641 - 642
  • [22] Long-term treatment with lumasiran: final results from the phase 2 open-label extension study
    Frishberg, Yaacov
    Groothoff, Jaap W.
    Hulton, Sally-Anne
    Harambat, Jerome
    Hogan, Julien
    Anne-Laure, Sellier-Leclerc
    Hayes, Wesley
    Coenen, Martin
    Willey, Richard
    Gansner, John
    Magen, Daniella
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [23] Long-term treatment with lumasiran: final results from the phase 2 open-label extension study
    Frishberg, Yaacov
    Groothoff, Jaap W.
    Hulton, Sally-Anne
    Harambat, Jerome
    Hogan, Julien
    Anne-Laure, Sellier-Leclerc
    Hayes, Wesley
    Coenen, Martin
    Willey, Richard
    Gansner, John
    Magen, Daniella
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I2390 - I2392
  • [24] Safety of Evobrutinib in Patients With Relapsing Multiple Sclerosis is Maintained in a Long-term Open-label Extension of a Phase II Study
    Montalban, Xavier
    Arnold, Douglas L.
    Weber, Martin S.
    Staikov, Ivan
    Piasecka-Stryczynska, Karolina
    Martin, Emily C.
    Mandel, Matthew
    Zima, Yulia
    Shaw, Jamie
    Dangond, Fernando
    Grenningloh, Roland
    Li, Ying
    Tomic, Davorka
    Wolinsky, Jerry S.
    NEUROLOGY, 2021, 96 (15)
  • [25] Association of Baseline Spinal Cord Area and Brain Volume With Long-Term Disability Progression in Ozanimod-Treated Participants With Relapsing Multiple Sclerosis: Final Analysis From the DAYBREAK Open-label Extension Study
    Filippi, Massimo
    Henry, Roland
    Arnold, Douglas
    Granziera, Cristina
    Kappos, Ludwig
    Sheffield, James
    Cheng, Chun-Yen
    Riolo, Jon
    Pachai, Chahin
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 922 - 923
  • [26] LONG-TERM PERAMPANEL USE IN OPEN-LABEL EXTENSION STUDIES
    Rektor, Ivan
    Krauss, Gregory L.
    Inoue, Yushi
    Kaneko, Sunao
    Williams, Betsy
    Patten, Anna
    Bibbiani, Francesco
    Laurenza, Antonio
    Wechsler, Robert T.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 : A23 - A23
  • [27] LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Banerji, A.
    Hao, J.
    Yu, M.
    Bernstein, J.
    Johnston, D.
    Riedl, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S21 - S21
  • [28] Teriflunomide in paediatric patients with relapsing multiple sclerosis: results from the open-label TERIKIDS extension
    Chitnis, T.
    Banwell, B.
    Kappos, L.
    Arnold, D.
    Gucuyener, K.
    Deiva, K.
    Saubadu, S.
    Hu, W.
    Benamor, M.
    Le-Halpere, A.
    Truffinet, P.
    Tardieu, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 65 - 65
  • [29] Long-term Efficacy and Safety, Including COVID-19 Infections, Among Ozanimod-Treated Patients With Relapsing Multiple Sclerosis in the DAYBREAK Open-Label Extension Trial
    Cree, B. A.
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Cheng, C.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 85 - 86
  • [30] Predictors of Relapse in Ozanimod-Treated Patients With Multiple Sclerosis: Post Hoc Analysis From the Open-Label Extension DAYBREAK Study
    Coyle, Patricia
    Dunn, Jeffrey
    Kappos, Ludwig
    Sheffield, James
    Riolo, Jon
    Cheng, Chun-Yen
    Thorpe, Andrew
    Filippi, Massimo
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1036 - 1037
12345